Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23440867 | 1.00 | SLC6A3 (0.39) | SLC6A3CA1CA2CHRM1PTGER4 | |
| SCHEMBL29483744 | 0.88 | SLC6A3 (0.38) | SLC6A3PTGER4 | |
| SCHEMBL21647729 | 0.88 | SLC6A3 (0.38) | SLC6A3PTGER4 | |
| SCHEMBL23440877 | 0.86 | FFAR4 (0.39) | SLC6A3PTGER4 | |
| SCHEMBL23440879 | 0.86 | FFAR4 (0.39) | SLC6A3PTGER4 | |
| SCHEMBL21647801 | 0.86 | KIF11 (0.36) | SLC6A3CHRM1PTGER4 | |
| SCHEMBL21647800 | 0.86 | KIF11 (0.36) | SLC6A3CHRM1PTGER4 | |
| SCHEMBL30409321 | 0.86 | KIF11 (0.36) | SLC6A3CHRM1PTGER4 | |
| SCHEMBL21647752 | 0.81 | KDM4C (0.34) | SLC6A3PTGER4 | |
| SCHEMBL21647751 | 0.81 | KDM4C (0.34) | SLC6A3PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089532-A1 | BENZENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-03-24 | — | — | US | disclosed |
| US-11261154-B2 | Benzene derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-03-01 | — | — | US | disclosed |
| US-20210332009-A1 | BENZENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | US | disclosed |
| EP-3831810-A1 | BENZENE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2021-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261154-B2 | Benzene derivative | PMP22, TMBIM6, MYT1 | SLC6A3 2855/4885CA1 4171/4885CA2 2728/4885 |
| US-20210332009-A1 | BENZENE DERIVATIVE | PMP22, TMBIM6, MYT1 | SLC6A3 2855/4885CA1 4171/4885CA2 2728/4885 |
| US-20220089532-A1 | BENZENE DERIVATIVE | PMP22, TMBIM6, MYT1 | SLC6A3 2855/4885CA1 4171/4885CA2 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.